COSM

Cosmos Health is a $12M micro-cap pharma wholesaler/nutraceutical distributor whose top line is the only encouraging line in the whole file: FY2025 revenue grew 19.9% to $65.3M and gross profit jumped 83% to $7.9M. But that revenue is low-quality distribution volume — gross margin is just 12.1%, and everything below it is red. The company posted a -$19.1M net loss (its worst of a five-year unbroken losing streak: -$8.0M, -$13.8M, -$18.5M, -$16.2M, -$19.1M), a -25.6% operating margin, and -29.3% net margin. Accumulated deficit sits at -$133M against only $18.4M of equity, and ROE is -103.9%. This is not a business that has ever demonstrated it can make money at scale.

The balance sheet is the disqualifier. Cash is a razor-thin $716K against a -$8.45M annual operating cash burn — i.e., roughly one month of runway from cash on hand. Liabilities grew 58% to $47.1M while equity shrank 25% to $18.4M, pushing liabilities/equity to 2.55x, and current assets ($38.4M) barely cover current liabilities ($38.3M). The only reason the equity line is still positive is relentless dilution: shares outstanding rose 86.3% in a single year to 50.8M. Management's own MD&A says the quiet part out loud — 'Failure to raise new capital will have a significant impact on the non-implementation of the required investments... the growth of the Company's activity, its financial results and its financial situation will be negatively affected.' Translation: the model does not self-fund, and survival depends on continued capital raises that dilute existing holders.